文献速递间质性肺疾病

进行性肺纤维化:最新综述

Progressive pulmonary fibrosis: a state-of-the-art review.
PubMed 文献 · Eur Respir J · 2026-09-25

纤维化性间质性肺病包括多种疾病,以特发性肺纤维化(IPF)为原型。非IPF纤维化性间质性肺病患者中相当比例会发展为类似IPF的进行性表型,即进行性肺纤维化(PPF),其病程与IPF相似。2019年3期试验显示尼达尼布可延缓PPF疾病进展,2022年国际指南给予尼达尼布条件性推荐,2025年奈兰度司特进一步减少疾病进展。

要点

  • PPF指非IPF纤维化性间质性肺病出现类似IPF的进行性表型。
  • 尼达尼布获2022年国际指南条件性推荐用于治疗PPF。
  • 早期识别PPF有助于及时启动抗纤维化治疗及综合管理。

核心结论

  • PPF病程与IPF相似,表现为呼吸道症状加重、肺功能下降、生活质量受损和早亡。
  • 尼达尼布和奈兰度司特可减少PPF疾病进展,吡非尼酮可能也有获益。

研究设计与样本

  • 综述总结了纤维化性间质性肺病中PPF的概念、临床试验证据和指南推荐。
  • 2019年3期试验评估尼达尼布对PPF的疗效,以1年内用力肺活量下降衡量疾病进展。
  • 2025年研究显示磷酸二酯酶4B抑制剂奈兰度司特进一步减少PPF疾病进展。

主要发现

  • 尼达尼布治疗使1年内用力肺活量下降所衡量的疾病进展减半。
  • 奈兰度司特进一步减少PPF患者疾病进展。
  • 其他较小试验提示吡非尼酮可能使PPF患者获益。

关键数值与推荐

  • 2022年国际临床实践指南对尼达尼布治疗PPF患者给予条件性推荐。

临床怎么用

  • 诊断为PPF可识别纤维化疾病进展患者,应早期识别以及时启动抗纤维化治疗。
  • 符合条件者应考虑肺移植,并提供整体照护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibrosing interstitial lung disease encompasses a large number of diverse conditions, the prototype being idiopathic pulmonary fibrosis (IPF). IPF is characterised by irreversible progression and accounts for loss of lung function, exercise intolerance and complications, especially acute exacerbation and respiratory failure leading to early mortality. A significant proportion of patients with fibrosing interstitial lung diseases other than IPF will develop a progressive phenotype comparable to IPF. Progression occurs despite conventional treatment, which, depending on the underlying condition, may include close monitoring, antigen eviction, glucocorticoids, immunosuppressive therapy and pulmonary rehabilitation. Progressive pulmonary fibrosis (PPF) has a disease course similar to IPF, with worsening respiratory symptoms, decline in lung function, impairment of quality of life and premature death. In 2019, a phase 3 trial demonstrated that treatment with the tyrosine kinase inhibitor nintedanib halves disease progression as measured by a decline in forced vital capacity over 1 year, and contributed to the validation of the PPF concept. In the 2022 international clinical practice guideline, nintedanib received a conditional recommendation for treating patients with PPF. In 2025, it was demonstrated that the phosphodiesterase 4B inhibitor nerandomilast further reduces disease progression in patients with PPF. Other smaller trials have suggested that pirfenidone may also benefit patients with PPF. Several newer compounds are currently being developed for both IPF and PPF. Because a diagnosis of PPF identifies patients with fibrotic disease progression, early identification is warranted for the timely initiation of antifibrotic therapy, consideration of lung transplantation if eligible, and holistic care.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Cottin V, Brown K, Flaherty KR, et al. Progressive pulmonary fibrosis: a state-of-the-art review. Eur Respir J. 2026. PMID: 42276742. doi:10.1183/13993003.01557-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。